EPIDEMIOLOGICAL, CLINICAL AND FINANCIAL COMPONENTS OF RESULTS OF LONGTERM ANTIRETROVIRAL THERAPY OF PATIENTS WITH HIV-INFECTION

The aim of the study was to analyze the results of long-term antiretroviral therapy (ARV) in patients with HIV-infection basing on epidemiological, clinical and economical parameters in the Northwestern Federal District (NFD) of Russia. Materials and methods. Epidemiogical analysis was conducted using the data of reports from 10 NFD regions in the period from 2005 to 2018: morbidity rate, prevalence of HIV-infection, number of people living with HIV-infection (PLWH) and being under regular medical  check-up. For clinical analysis were used some key indices of ARV effectiveness such as patients’ therapy coverage, clinical stages of HIV-infection, mortality rate and lethality rate in patients. Health costs were calculated basing on ARV procurement in the District from federal and regional programs as well as from funds allocated on diagnostic products and prevention programs. Study results. On the top of  administered ARV, rates of mortality and prevalence of HIV-infection in the RF and NFD had increasing tendency. The rate of mortality in PLWH increased in several times while the lethality rate changed insignificantly. Number of PLWH on the stage of clinical signs grew sixfold reaching 63,1%. Questionnaire survey was held in 74 infectious disease physicians with the following estimation of values of some reasons of low effectiveness of ARV and  transformation of epidemic into severe and comorbid forms. By reason rating, low ARV coverage in patients was the most common, late detection of HIV-infection and treatment onset, poor adherence and therapy discontinuation, qualified staff shortage, low accessibility of medical organizations, insufficient choice and quality of ARV. In considering financial costs on ARV, insufficient appropriation of funds and insufficient support of other activities including organizational and preventive measures were revealed.

HIV, antiretroviral therapy, epidemiology, clinic, pharmacoeconomics

1. Belyakov N.A., Rassokhin V.V. Comorbid conditions in HIV infection. St. Petersburg: Baltic medical educational center, 2019, Part 2, 252 р. (In Russ.).

2. HIV infection and comorbid conditions in the NorthWestern Federal district of the Russian Federation in 2017. Analytical review under N.A.Belyakov. Saint Petersburg: Institute of epidemiology and Microbiology named after Pasteur, 2018, 52 р. (In Russ.).

3. Stepanova E.V., Leonova O.N., Kizhlo S.N., Sizova N.V. Reasons for switching highly active antiretroviral therapy circuits. HIV infection and immunosuppression, 2011, Vol. 3, No. 3, рр. 58–62 (In Russ.).

4. Tedstrom D., Narkevich M.I. Why should solving the problem of HIV AIDS become one of the priorities of Russian policy? Far Eastern journal of infectious pathology, 2004, No. 4 (4), рр. 6–13 (In Russ.).

5. Babikhina K.B., Vergus G.S., Golovin S.E., Dzhakoniya G.V., Dragunova Yu.A., Egorova N.V., Mikhailov A.V., Skvortsov A.S., Khan T.A., Khilko N.N. HIV infection and immunosuppression, 2016, Vol. 8, No. 2, рр. 84–95 (In Russ.).

6. UNAIDS. «90-90-90» is an ambitious treatment goal aimed at ending the AIDS epidemic. 2013. 2016.

7. Kubaeva M.B., Gushchina Yu.Sh. Pharmacoeconomical analysis of the cost of antiretroviral drugs used in the treatment of HIV-infected patients. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology, 2017, Vol. 10, No. 2, рр. 41–43 (In Russ.).

8. The Federal Antimonopoly service has achieved a reduction in prices for 239 drugs for the treatment of HIV, tuberculosis and viral hepatitis. Remedium. Journal of the Russian market of medicines and medical equipment, 2017, No. 4, рр. 4–5 (In Russ.).

9. Rassokhin V.V., Ogurtsova S.V., Bobreshova A.S. Economics of HIV medicine in 2016. How to allocate limited resources? Medical academic journal, 2016, Vol. 16, No. 1, рр. 102–105 (In Russ.).

10. Bulankov Yu. I., Sergalieva A. Sh. Branded and generic antiretroviral drugs in the treatment of HIV infection. Health is the basis of human potential: problems and ways of their solution, 2012, Vol. 7, No. 2, рр. 750 (In Russ.).

11. BorodulinaE.A., Tsygankov I.L., Borodulin B.E., Vdoushkina E.S., Borodulina E.V. Drug Addiction, HIV, tuberculosis. Features of multimorbidity in modern conditions. Bulletin of modern clinical medicine, 2014, Vol. 7, No. 4, рр. 18–21 (In Russ.).

12. Ghosn J., Frange P., Bayan T., Tran L., Meyer L., Meixenberger K., Krastinova E., Monforte A.A., Zangerle R., de Mendoza C., Porter K., Chaix M.L., Burns F., Chene G., Costagliola D., Giaquinto C., Grarup J., Kirk O., Bailey H., Anne A.V., Panteleev A et al. CD4 T-cell decline following hiv seroconversion in individuals with and without cxcr4-tropic virus // Journal of Antimicrobial Chemotherapy. 2017. Т. 72. № 10. С. 2862–2868.

13. Azovtseva O.V., Buzunova S.A., Arkhipov G.S., Arkhipova E.I., Trofimova T.S. Experience of combined antiviral therapy of chronic hepatitis C in HIV-infected patients in the Novgorod region. Bulletin of the peoples friendship University of Russia. Series: Medicine, 2014, No. 1, рр. 18–24 (In Russ.).

14. Demchilo A.P., Mitsura V.M., Kozorez E.I., Zhavoronok S.V., Boriskin I.V. Long-term results of chronic viral hepatitis C in HIV-infected patients. ARSmedica, 2009, No. 8, рр. 75–78 (InRuss.).

15. Zakharova N.G., Dvorak S.I., Plavinsky S.L., Toropov S.E., Rassokhin V.V., Belyakov N.A. The Causes of adverse outcomes in patients with HIV infection who took highly active antiretroviral. Part 1. HIV infection and immunosuppression, 2015, Vol. 7, No. 3, рр. 48–55 (In Russ.).

16. Zakharova N.G., Dvorak S.I., Guba Z.V., Plavinsky S.L., Rassokhin V.V., Belyakov N.A., Toropov S.E. Causes of adverse outcomes in patients with HIV infection who took highly active antiretroviral. Part 2. HIV infection and immunosuppression, 2015, Vol. 7, No. 4, рр. 52–63 (In Russ.).

17. Leonova O.N., Rassokhin V.V., Rakhmanova A.G. Analysis of deaths in patients with HIV infection based on the materials of the Department of palliative medicine. HIV infection and immunosuppression, 2009, Vol. 1, No. 2, рр. 63–68 (In Russ.).

18. Littlefield A.K., Brown J.L., DiClemente R.J., Sales J.M., Rose E.S., Safonova P., Belyakov N., Rassokhin V.V. Phosphatidylethanol (peth) as a biomarker of alcohol consumption in hiv-infected young russian women: comparison to self-report assessments of alcohol use // AIDS and Behavior. 2017. Vol. 21, No. 7. Р. 1938–1949.

19. Jarrin I., Del Amo J., Pantazis N., Dalmau J., Blanco J., Martinez-Picado J., Phillips A.N., Olson A., Porter K., Mussini C., Boufassa F., Costagliola D., Kelleher T., Cooper D., Finlayson R., Bloch M., Ramacciotti T., Gelgor L., Smith D., Zangerle R., Panteleev A. et al. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? AIDS, 2015, Vol. 29, No. 17, рр. 2323–2333.

20. Boeva E.V., Belyakov N.A. Immune recovery Syndrome in HIV infection. Infection and immunity, 2018, Vol. 8, No. 2, рр. 139–149 (In Russ.).

21. Brown J.L., DiClemente R.J., Sales J.M., Rose E.S., Safonova P., Rassokhin V.V., Levina O.S., Belyakov N. Substance use patterns of HIVinfected russian women with and without hepatitis c virus co-infection // AIDS and Behavior. 2016. Vol. 20, No. 10. Р. 2398–2407.

22. Zagdyn Z.M., Verbitskaya E.V., Sokolovich E.G., Belyakov N.A. Comprehensive assessment of the effectiveness of the system of combating the spread of HIV tuberculosis in the North-West of Russia. Tuberculosis and lung disease, 2019, Vol. 97, No. 3, рр. 6–15 (In Russ.).

23. Ivanov A.K., Nechaev V.V., Pozhidaeva L.N., NazarovV.Yu. Lethality of patients with a combination of tuberculosis, viral hepatitis and HIV infection. Medical Alliance, 2015, No. 1, рр. 167–169 (In Russ.).

24. Caro-Vega Y., Sierra-Madero J., Crabtree-Ramírez B., Schultze A., Mocroft A., Efsen A.M.W., Podlekareva D.N., Lundgren J.D., Kirk O., Post F.A., Panteleev A., Skrahin A., Miro J.M., Girardi E., Toibaro J., Losso M.H., Andrade-Villanueva J., Tetradov S., Fehr J., Caylà J. et al. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe аnd Latin America // BMC Infectious Diseases. 2018. Vol. 18. No. 1. Р. 191.

25. Moiseev S.V., Maksimov S.L., Abdurakhmanov D.T. Chronic hepatitis B in HIV-infected people. Clinical pharmacology and therapy, 2014, Vol. 23, No. 2, рр. 5–12 (In Russ.).

26. Kytmanova L., Moskvicheva M. Prevalence of drug addiction and the main trends of the epidemic process in HIV infection and hepatitis C. Doctor, 2015, No. 1, рр. 83–86 (In Russ.).

27. Pokrovsky V.V., Ladnaya N.N., Sokolova E.V., Trushina O.I., Buravtsova E.V. HIV infection. Newsletter, No. 39. Moscow: Federal AIDS center, 2014, 52 р. (In Russ.).

28. Vorontsov D.V., Matuzkova A.N., Morgacheva Y.V., Saukhat S.R. Formation of adherence of HIVinfected patients to antiretroviral therapy in the system of preventive and antiepidemic measures. Far Eastern journal of infectious pathology, 2015, No. 29 (29), рр. 65–74 (In Russ.).

29. Miroshnikov A.E., Khokhlov A.L., Antipova N.P. Influence of alcohol and psychoactive substances on adherence and results of treatment of patients with HIV infection. Biomedicine, 2010, No. 3, рр. 102–104 (InRuss.).

30. Musatov V.B., Yakovlev A.A., Chaika N.A., Kelly D., Amirkhanyan Yu.А. The Main causes and modern methods of correction of low adherence to antiretroviral therapy in difficult patients. HIV infection and immunosuppression, 2018, Vol. 10, No. 4, рр. 37–56 (In Russ.).

31. Tyusova O.V., Blokhina E.A., Grinenko A.Ya., Zvartau E.E., Lioznov D.A., Ray A., Cheng D., Bridden K., Cheisson K., Valey A., Palfay T., Queen E., Samet D., Krupitsky E.M. Randomized clinical trial of behavioral intervention for HIV-infected patients who abuse alcohol. Questions of narcology, 2017, No. 12 (160), рр. 23–43 (In Russ.).

32. Toropov S.E., Zakharova N.G., Stepanova E.V., Vinogradova T.N., Rassokhin V.V., Leonova O.N., Denisova M.A., Belyakov N.A. Economics and clinical pharmacological abcven analysis of therapy of patients with HIV infection. HIV infection and immunosuppression, 2013, Vol. 5, No. 4, рр. 30–36 (In Russ.).

33. Ustinov A.S., Pecoraro A., Mimiaga M., O’clayrich K., Safaryan S. Substance Use and depression in HIV patients committed to and interrupted antiretroviral therapy. Neurological Bulletin. Journal V. M. Bekhtereva, 2016, Vol. 48, No. 2, рр. 5–11 (In Russ.).

34. Stepanova E.V., Zakharova N.G., Toropov S.E., Minin P.V. Side effects and optimization of highly active antiretroviral therapy based on the materials of the St. Petersburg AIDS center. HIV infection and immunosuppression, 2012, Vol, No. 3, рр. 101 (In Russ.).

35. Kasatkina V., Cherkashnev R. Financing of activities aimed at combating the spread of HIV and AIDS. In the collection // Нealth financing, problems and prospects. Tambov, 2017, рр. 75–82 (In Russ.).

36. Obukhova O.V. Financing of measures to counteract HIV infection. Medical technology. Evaluation and selection, 2012, No. 1 (7), рр. 47–53 (In Russ.).

37. Pape U. The Role of non-governmental organizations in combating HIV AIDS in Russia. Journal of social policy research, 2010, Vol. 8, No. 2, рр. 203–226 (In Russ.).

38. Nechaeva O.B., Podymova A.S. The impact of HIV infection on the demographic situation in Russia. Medical Alliance, 2018, No. 1, рр. 6–16 (In Russ.).

39. Ulumbekova G.E. Health of Russia. What to do. 2nd edition. Moscow: GEOTAR-Мedia, 2015, 704 р. (InRuss.).

40. Kanestri V.G., Kravchenko A.V., Kushakova T.E., Chukaeva I.I. Metabolic disorders in HIV patients receiving antiretroviral therapy. Infectious disease, 2014, Vol. 12, No. 4, рp. 5–10 (In Russ.).

41. Ivanova O.G., Mordyk A.V., Krasnova E.I. Risk Factors for adverse disease outcome in patients with HIV-associated tuberculosis. Journal of Siberian Medical Sciences, 2019, No. 3, рр. 33–43 (In Russ.).

42. Starodubov V.I., Obukhova O.V., Nosova E.A. Application of statistical observation tools to assess the dependence of funding and epidemiological data on HIV infection in the Russian Federation. Regional economy, 2009, No. 1 (17), рр. 22–27 (In Russ.).

43. Chereshnev V.A., Verzilin D.N., Maksimova T.G., Chereshneva E.V. Socio-economic monitoring of the threat of HIV/AIDS in the Russian Federation. Regional economy, 2012, No. 2 (30), рр. 153–169 (In Russ.).